FDA Social Media Review From Dose Of Digital

Post on 14-Dec-2014

3.919 views 1 download

description

A handful of new information came out at the FDA pharma social media hearings, but quite a bit was missing as well. Here's my brief overview of what I learned and what I thought was missing

Transcript of FDA Social Media Review From Dose Of Digital

Three Things I Learned at the FDA Hearings and Three I Wish I Had

Jonathan RichmanDirector of Strategic Planning, Bridge WorldwideAuthor, Dose of Digital@jonmrich

Yes, I was there...

...along with 60+ of my close friends

Two themes

What I learned What I didn’t(but wish I had)

What I learned

The FDA gets itMedWatch is deadConsumers might actually want us there

(a serious AE, BTW)

What I didn’t

FDA’s plan for keeping upThe end of red herringsWhat pharma REALLY wants to do

What I learned

The FDA gets itMedWatch is deadConsumers might actually want us there

The FDA gets it

The FDA gets it

“Since the 1996 public meeting, there has been a massive expansion of new tools and technologies, such as blogs, microblogs, podcasts, social network sites (‘social networks’) and online communities, video sharing, widgets, and wikis...”

The FDA gets it

1. For what online communications is pharma accountable?

2. How can pharma follow the rules in using tools with space limitations and real-time comms?

3. What rules apply to the posting of corrective info on websites controlled by third parties?

4. When is the use of links appropriate? 5. Questions specific to Internet adverse event

reporting

MedWatch is dead

MedWatch is dead

Courtesy of Ignite Health

MedWatch is dead

Consumers might actually want us there

AGREE that healthcare companies’ use of social media...

...provides important updates on products and services – 79%

...brings accurate information into conversations about drugs or devices – 73%

...addresses frequently asked questions about products and services – 66%

...adds valuable professional expertise to the conversation – 62%

Good News

Consumers might actually want us there

If I double the dose, would the blisters go away faster?If I double the dose, would the blisters go away faster?

Double your dose and see what happens, but I wouldn’t hold my breath.Double your dose and see what happens, but I wouldn’t hold my breath.

Consumers might actually want us there

AGREE healthcare companies... ...should monitor and correct misperceptions or

misinformation when that info can be harmful – 90% ...should be responsible for policing any unauthorized

versions of their content – 64%

Bad News

Consumers might actually want us there

In short...

To whom much is given, much is expected.

What I didn’t

FDA’s plan for keeping upThe end of the red herringsWhat pharma REALLY wants to do

FDA’s plan for keeping up

FDA’s plan for keeping up

FDA’s plan for keeping up

FDA’s plan for keeping up

FDA’s plan for keeping up

19962022

2009

FDA Technology-RelatedHearings Schedule

FDA’s plan for keeping up

19962022

2009

FDA Technology-RelatedHearings Schedule

The end of red herrings

Only 1 in 500 posts qualifies as a “reportable adverse event”

The end of red herrings

Source: Nielsen BuzzMetrics, Personal Communications

Nielsen BuzzMetrics total Healthcare discussions (~1,350 sites):

82,697 per day

Percentage of posts with a reportable adverse event:

0.2%

Number of reportable adverse events for the ENTIRE INDUSTRY:

166 per day

The end of red herrings

Adverse event reportingOff label discussionsPersonal identifying informationMonitoring volume and resourcesFTC regulationsTechnology integrationNo clear precedentsLack of internal expertise

The end of red herrings

What pharma REALLY wants to do

?

What pharma really wants to do

?

?

What pharma really wants to do

What pharma really wants to do

?

What pharma really wants to do

?

What pharma really wants to do

1. For what online communications is pharma accountable?

2. How can pharma follow the rules in using tools with space limitations and real-time comms?

3. What rules apply to the posting of corrective info on websites controlled by third parties?

4. When is the use of links appropriate? 5. Questions specific to Internet adverse event

reporting

What pharma really wants to do

Does allowing additional leeway for pharma to participate in social media improve or harm public health?

Three Things I Learned at the FDA Hearings and Three I Wish I Had

Contact Me

Text Healthcare to 50500

Jonathan Richman513.253.1295j.richman@bridgeworldwide.comTwitter: @jonmrichThis presentation: http://bit.ly/dodfda

http://www.doseofdigital.com http://www.bridgeworldwide.com

Contact Me